Even after a trial begins, the FDA, IRBs, and other necessary review boards will continue to monitor and receive updates on the trial to make sure that all safety protocols are being practiced at all times. They may also intervene if necessary upon the report of a participant having adverse reactions, therefore indicating the testing could be harmful to study subjects. The FDA or company overseeing the clinical trial has the legal authority and obligation to cease any trial deemed unsafe upon the discovery that the new treatment or drug could be harmful. In rare cases, trials are even cut shorter than usual if the candidate drug is performing phenomenally well as it would be deemed unethical to withhold it from the patients in the trial that are not receiving it currently. This would help researchers fast-track the development and study of the new drug or treatment.
This post was written by ClinicalTrialAdmin